Share Search
Visit the Share Search
Mike Barker installed as finance chief at Tissue Regenix
28th Aug 2019 16:00
(Sharecast News) - Regenerative medical devices company Tissue Regenix Group announced the appointment of Mike Barker as its chief financial officer on Wednesday.
The AIM-traded firm said Barker would join the group as CFO and as an executive director on the board with immediate effect, having supported the company since the beginning of the year as interim finance director.
It said Barker, a Chartered Accountant for more than 20 years, was bringing experience of both AIM-listed and private businesses with him.
After training with Deloitte, he reportedly spent 10 years in its corporate finance advisory business working on private equity transactions, before setting up his own consultancy business to assist small to medium enterprises in the delivery of strategic plans.
During that time, Tissue Regenix said he worked "closely" with the management team of Quantum Pharma - a UK manufacturer and supplier of unlicensed medicines and hard-to-source products, acquired by Clinigen Group in 2017, to deliver strategic projects before holding the position of group corporate development director.
"It's a pleasure to welcome Mike to the executive team," said executive director John Samuel.
"He is well acquainted with the business, having supported the group since the beginning of the year.
"His experience in AIM listed businesses and contribution to strategic planning will augment and strengthen our management and executive teams as we continue to improve the efficiency of our operations across the business to meet the increasing demand for our products."
The AIM-traded firm said Barker would join the group as CFO and as an executive director on the board with immediate effect, having supported the company since the beginning of the year as interim finance director.
It said Barker, a Chartered Accountant for more than 20 years, was bringing experience of both AIM-listed and private businesses with him.
After training with Deloitte, he reportedly spent 10 years in its corporate finance advisory business working on private equity transactions, before setting up his own consultancy business to assist small to medium enterprises in the delivery of strategic plans.
During that time, Tissue Regenix said he worked "closely" with the management team of Quantum Pharma - a UK manufacturer and supplier of unlicensed medicines and hard-to-source products, acquired by Clinigen Group in 2017, to deliver strategic projects before holding the position of group corporate development director.
"It's a pleasure to welcome Mike to the executive team," said executive director John Samuel.
"He is well acquainted with the business, having supported the group since the beginning of the year.
"His experience in AIM listed businesses and contribution to strategic planning will augment and strengthen our management and executive teams as we continue to improve the efficiency of our operations across the business to meet the increasing demand for our products."